Document Number: 026

Overview
The purpose of this document is to describe the guidelines AllWays Health Partners utilizes to determine treatments that are considered experimental and investigational.

Coverage Guidelines
AllWays Health Partners covers services, procedures, devices, biologic products, and drugs (collectively “treatment”) when there is sufficient scientific evidence to support their use or when the treatment is required by regulation.

The following guidelines are utilized to determine the extent to which scientific evidence is sufficient to support a treatment:

1. The treatment must have a final approval from the appropriate government regulatory bodies (for example, the Food and Drug Administration); and
2. The scientific evidence must demonstrate that conclusions pertaining to a treatment are based on sound scientific study methodology published in credible, peer-reviewed English-language journals. The following hierarchy of reliable evidence is used:
   a. Systematic reviews and/or high-quality Meta analyses of randomized controlled trials with definitive results
   b. Formal high-quality technology assessments
   c. Well-designed, randomized, controlled, double-blind studies
   d. Cohort studies
   e. Case-control studies
   f. Expert opinion from national professional medical societies or national medical policy organizations in the absence of definitive scientific data

Note: With respect to clinical studies, only those articles containing scientifically valid data and published in the credible, peer-reviewed medical and scientific literature shall be considered reliable evidence. Specifically, not included in the meaning of reliable evidence are reports, articles, or statements by providers or groups of providers containing only abstracts, anecdotal evidence, or personal professional opinions. Also, not included in the meaning of reliable evidence is when a provider or a number of providers have elected to adopt a device, medical treatment, or procedure as their personal treatment or procedure of choice or standard of practice.

3. The treatment must be proven to be safe and effective:
   a. Beneficial effects on health outcomes must outweigh any harmful effects
b. Health outcomes are superior or comparable to established alternatives

c. Improvement in health outcomes have the potential to be realized outside the
investigational setting

d. It is as cost effective as established treatments that produce similar outcomes

Exclusions
No benefits or reimbursement are provided for health care charges that are received for, or related to, care
that AllWays Health Partners considers experimental and investigational services or procedures.

Definitions
Experimental or Investigational: A treatment, service, procedure, supply, device, biologic product, or drug
(collectively “treatment”) is experimental or investigational when scientific evidence to support its use is
insufficient.

Relevant Regulations
Public Law 111 - 148 - Patient Protection and Affordable Care Act, Section 2709. Coverage for a Clinical
Trial.

(a) COVERAGE. —

(1) IN GENERAL. —If a group health plan or a health insurance issuer offering group or
individual health insurance coverage provides coverage to a qualified individual, then
such plan or issuer—

(A) may not deny the individual participation in the clinical trial referred to in
subsection (b)(2);

(B) subject to subsection (c), may not deny (or limit or impose additional
conditions on) the coverage of routine patient costs for items and services
furnished in connection with participation in the trial; and

(C) may not discriminate against the individual on the basis of the individual’s
participation in such trial.

(2) ROUTINE PATIENT COSTS. —

(A) INCLUSION. —For purposes of paragraph (1)(B), subject to subparagraph (B),
routine patient costs include all items and services consistent with the coverage
provided in the plan (or coverage) that is typically covered for a qualified
individual who is not enrolled in a clinical trial.

(B) EXCLUSION. —For purposes of paragraph (1)(B), routine patient costs does
not include—

i. the investigational item, device, or service, itself;

ii. items and services that are provided solely to satisfy data collection and
analysis needs and that are not used in the direct clinical management of
the patient; or
iii. a service that is clearly inconsistent with widely accepted and established standards of care for a particular diagnosis.

(3) USE OF IN-NETWORK PROVIDERS. —If one or more participating providers is participating in a clinical trial, nothing in paragraph (1) shall be construed as preventing a plan or issuer from requiring that a qualified individual participate in the trial through such a participating provider if the provider will accept the individual as a participant in the trial.

(4) USE OF OUT-OF-NETWORK. —Notwithstanding paragraph (3), paragraph (1) shall apply to a qualified individual participating in an approved clinical trial that is conducted outside the State in which the qualified individual resides.

(b) QUALIFIED INDIVIDUAL DEFINED. —For purposes of subsection (a), the term ‘qualified individual’ means an individual who is a participant or beneficiary in a health plan or with coverage described in subsection (a)(1) and who meets the following conditions:

(1) The individual is eligible to participate in an approved clinical trial according to the trial protocol with respect to treatment of cancer or other life-threatening disease or condition.

(2) Either—

   (A) the referring health care professional is a participating health care provider and has concluded that the individual’s participation in such trial would be appropriate based upon the individual meeting the conditions described in paragraph (1); or

   (B) the participant or beneficiary provides medical and scientific information establishing that the individual’s participation in such trial would be appropriate based upon the individual meeting the conditions described in paragraph (1).

(c) LIMITATIONS ON COVERAGE. —This section shall not be construed to require a group health plan, or a health insurance issuer offering group or individual health insurance coverage, to provide benefits for routine patient care services provided outside of the plan’s (or coverage’s) health care provider network unless out-of-network benefits are otherwise provided under the plan (or coverage).

(d) APPROVED CLINICAL TRIAL DEFINED. —

   (1) IN GENERAL. —In this section, the term ‘approved clinical trial’ means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or condition and is described in any of the following subparagraphs:

      (A) FEDERALLY FUNDED TRIALS. —The study or investigation is approved or funded (which may include funding through in-kind contributions) by one or more of the following:
i. The National Institutes of Health.
ii. The Centers for Disease Control and Prevention.
iii. The Agency for Health Care Research and Quality.
iv. The Centers for Medicare & Medicaid Services.
v. cooperative group or center of any of the entities described in clauses (i) through (iv) or the Department of Defense or the Department of Veterans Affairs.
vi. A qualified non-governmental research entity identified in the guidelines issued by the National Institutes of Health for center support grants.
vii. Any of the following if the conditions described in paragraph (2) are met:
    I. The Department of Veterans Affairs.
    II. The Department of Defense.
    III. The Department of Energy.

(B) The study or investigation is conducted under an investigational new drug application reviewed by the Food and Drug Administration.

(C) The study or investigation is a drug trial that is exempt from having such an investigational new drug application.

(2) CONDITIONS FOR DEPARTMENTS. —The conditions described in this paragraph, for a study or investigation conducted by a Department (“departments” as referenced above in vii.), are that the study or investigation has been reviewed and approved through a system of peer review that the Secretary (of the respective departments listed above in vii.) determines—

(A) to be comparable to the system of peer review of studies and investigations used by the National Institutes of Health, and

(B) assures unbiased review of the highest scientific standards by qualified individuals who have no interest in the outcome of the review.

(e) LIFE-THREATENING CONDITION DEFINED. —In this section, the term ‘life-threatening condition’ means any disease or condition from which the likelihood of death is probable unless the course of the disease or condition is interrupted.

General Laws of Massachusetts Part I, Title XXII Chapter 175: Section 47K – Off-label use drug use: cancer treatment

No individual policy of accident and sickness insurance issued pursuant to section one hundred and eight which provides coverage for prescription drugs, nor any group blanket policy of accident and sickness insurance issued pursuant to section one hundred and ten which provides coverage for prescription drugs, shall exclude coverage of any such drug used for the treatment of cancer on the grounds that the off-label use of the drug has not been approved by the United States Food and Drug Administration for that indication; provided, however, that such drug is recognized for treatment of such indication in one of
the standard reference compendia, or in the medical literature, or by the commissioner under the provisions of section forty-seven L.

General Laws of Massachusetts Part I, Title XXII Chapter 175: Sections 47O –HIV/AIDS treatment; insurance coverage for certain off-label use of prescription drugs
No individual policy of accident and sickness insurance issued or renewed pursuant to section one hundred and eight, which provides coverage for prescription drugs, nor any group blanket policy of accident and sickness insurance issued pursuant to section one hundred and ten which provides coverage for prescription drugs, shall exclude coverage of any such drug for HIV/AIDS treatment on the grounds that the off-label use of the drug has not been approved by the federal food and drug administration for that indication, if such drug is recognized for treatment of such indication in one of the standard reference compendia, or in the medical literature, or by the commissioner under the provisions of section forty-seven P of this chapter.

General Laws of Massachusetts Chapter 176G: Section 4G. Off-label use of prescription drugs for HIV/AIDS treatment
Any individual or group health insurance maintenance contract which provides coverage for prescription drugs shall provide coverage for off-label uses of prescription drugs used in the treatment of HIV/AIDS as set forth in sections forty-seven O and forty-seven P of chapter one hundred and seventy-five.

The following CPT/HCPCS procedure codes are investigational and unproven and therefore not covered.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20560</td>
<td>Needle insertion(s) without injection(s); 1 or 2 muscle(s)</td>
</tr>
<tr>
<td>20561</td>
<td>Needle insertion(s) without injection(s); 3 or more muscles</td>
</tr>
<tr>
<td>22526</td>
<td>Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single</td>
</tr>
<tr>
<td>22527</td>
<td>Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>22867</td>
<td>Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; single level</td>
</tr>
<tr>
<td>22868</td>
<td>Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; second level (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>22869</td>
<td>Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>22870</td>
<td>Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; second level (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>32994</td>
<td>Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation</td>
</tr>
<tr>
<td>33274</td>
<td>Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed</td>
</tr>
<tr>
<td>33275</td>
<td>Transcatheter removal of permanent leadless pacemaker, right ventricular</td>
</tr>
<tr>
<td>33289</td>
<td>Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed</td>
</tr>
<tr>
<td>34717</td>
<td>Endovascular repair of iliac artery at the time of aorto-iliac artery endograft placement by deployment of an iliac branched endograft including pre-procedure sizing and device selection, all ipsilateral selective iliac artery catheterization(s), all associated radiological supervision and interpretation, and all endograft extension(s) proximally to the aortic bifurcation and distally in the internal iliac, external iliac, and common femoral artery(ies), and treatment zone angioplasty/stenting, when performed, for rupture or other than rupture (eg, for aneurysm, pseudoaneurysm, dissection, arteriovenous malformation, penetrating ulcer, traumatic disruption), unilateral (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>34718</td>
<td>Endovascular repair of iliac artery, not associated with placement of an aorto-iliac artery endograft at the same session, by deployment of an iliac branched endograft, including pre-procedure sizing and device selection, all ipsilateral selective iliac artery catheterization(s), all associated radiological supervision and interpretation, and all endograft extension(s) proximally to the aortic bifurcation and distally in the internal iliac, external iliac, and common femoral artery(ies), and treatment zone angioplasty/stenting, when performed, for other than rupture (eg, for aneurysm, pseudoaneurysm, dissection, arteriovenous malformation, penetrating ulcer), unilateral</td>
</tr>
<tr>
<td>34839</td>
<td>Physician planning of a patient-specific fenestrated visceral aortic endograft requiring a minimum of 90 minutes of physician time</td>
</tr>
<tr>
<td>34841</td>
<td>Endovascular repair of visceral aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) by deployment of a fenestrated visceral aortic endograft and all associated radiological supervision and interpretation, including target zone angioplasty, when performed; including one visceral artery endoprosthesis (superior mesenteric, celiac or renal artery)</td>
</tr>
<tr>
<td>34842</td>
<td>Endovascular repair of visceral aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) by deployment of a fenestrated visceral aortic endograft and all associated radiological supervision and interpretation, including target zone angioplasty, when performed; including two visceral artery endoprostheses (superior mesenteric, celiac and/or renal artery[s])</td>
</tr>
<tr>
<td>34843</td>
<td>Endovascular repair of visceral aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) by deployment of a fenestrated visceral aortic endograft and all associated radiological supervision and interpretation, including target zone angioplasty, when performed; including three visceral artery endoprostheses (superior mesenteric, celiac and/or renal artery[s])</td>
</tr>
<tr>
<td>34844</td>
<td>Endovascular repair of visceral aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) by deployment of a fenestrated visceral aortic endograft and all associated radiological supervision and interpretation, including target zone angioplasty, when performed; including four or more visceral artery endoprostheses (superior mesenteric, celiac and/or renal artery[s])</td>
</tr>
<tr>
<td>34845</td>
<td>Endovascular repair of visceral aorta and infrarenal abdominal aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) with a fenestrated visceral aortic endograft and concomitant unibody or modular infrarenal aortic endograft and all associated radiological supervision and interpretation, including target zone angioplasty, when performed; including one visceral artery endoprosthesis (superior mesenteric, celiac or renal artery)</td>
</tr>
<tr>
<td>34846</td>
<td>Endovascular repair of visceral aorta and infrarenal abdominal aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) with a fenestrated visceral aortic endograft and concomitant unibody or modular infrarenal aortic endograft and all associated radiological supervision and interpretation, including target zone angioplasty, when performed; including two visceral artery endoprostheses (superior mesenteric, celiac and/or renal artery[s])</td>
</tr>
<tr>
<td>34847</td>
<td>Endovascular repair of visceral aorta and infrarenal abdominal aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) with a fenestrated visceral aortic endograft and concomitant unibody or modular infrarenal aortic endograft and all associated radiological supervision and</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>34848</td>
<td>Endovascular repair of visceral aorta and infrarenal abdominal aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) with a fenestrated visceral aortic endograft and concomitant unibody or modular infrarenal aortic endograft and all associated radiological supervision and interpretation, including target zone angioplasty, when performed; including four or more visceral artery endoprostheses (superior mesenteric, celiac and/or renal artery(s))</td>
</tr>
<tr>
<td>43257</td>
<td>Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease</td>
</tr>
<tr>
<td>43284</td>
<td>Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed</td>
</tr>
<tr>
<td>43285</td>
<td>Removal of esophageal sphincter augmentation device</td>
</tr>
<tr>
<td>53854</td>
<td>Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy</td>
</tr>
<tr>
<td>55874</td>
<td>Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed</td>
</tr>
<tr>
<td>58674</td>
<td>Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound guidance and monitoring, radiofrequency</td>
</tr>
<tr>
<td>62263</td>
<td>Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days</td>
</tr>
<tr>
<td>62264</td>
<td>Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day</td>
</tr>
<tr>
<td>64454</td>
<td>Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed</td>
</tr>
<tr>
<td>64566</td>
<td>Electrical percutaneous tibial nerve stimulation (PTNS) is a peripheral technique that achieves its effect by periodic percutaneous stimulation of the posterior tibial nerve.</td>
</tr>
<tr>
<td>64624</td>
<td>Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>64625</td>
<td>Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)</td>
</tr>
<tr>
<td>64722</td>
<td>Decompression; unspecified nerve(s) (specify)</td>
</tr>
<tr>
<td>76391</td>
<td>Magnetic resonance (eg, vibration) elastography</td>
</tr>
<tr>
<td>76981</td>
<td>Ultrasound, elastography; parenchyma (eg, organ)</td>
</tr>
<tr>
<td>76982</td>
<td>Ultrasound, elastography; first target lesion</td>
</tr>
<tr>
<td>76983</td>
<td>Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>80145</td>
<td>Adalimumab</td>
</tr>
<tr>
<td>80187</td>
<td>Posaconazole</td>
</tr>
<tr>
<td>80230</td>
<td>Infliximab</td>
</tr>
<tr>
<td>80235</td>
<td>Lacosamide</td>
</tr>
<tr>
<td>80280</td>
<td>Vedolizumab</td>
</tr>
<tr>
<td>80285</td>
<td>Voriconazole</td>
</tr>
<tr>
<td>81283</td>
<td>IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant</td>
</tr>
<tr>
<td>81309</td>
<td>PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)</td>
</tr>
<tr>
<td>81328</td>
<td>SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)</td>
</tr>
<tr>
<td>81346</td>
<td>TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)</td>
</tr>
<tr>
<td>81490</td>
<td>Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score</td>
</tr>
<tr>
<td>81525</td>
<td>Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score</td>
</tr>
<tr>
<td>81541</td>
<td>Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score</td>
</tr>
<tr>
<td>86357</td>
<td>Natural killer (NK) cells, total count</td>
</tr>
<tr>
<td>87563</td>
<td>Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma genitalium, amplified probe technique</td>
</tr>
<tr>
<td>90587</td>
<td>Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use</td>
</tr>
<tr>
<td>90619</td>
<td>Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>90694</td>
<td>Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90880</td>
<td>Hypnotherapy</td>
</tr>
<tr>
<td>91112</td>
<td>Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report,</td>
</tr>
<tr>
<td>92145</td>
<td>Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report</td>
</tr>
<tr>
<td>93050</td>
<td>Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive</td>
</tr>
<tr>
<td>93264</td>
<td>Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care</td>
</tr>
<tr>
<td>93356</td>
<td>Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)</td>
</tr>
<tr>
<td>93702</td>
<td>Bioimpedance spectroscopy (BIS), extracellular fluid analysis for lymphedema assessment(s)</td>
</tr>
<tr>
<td>93740</td>
<td>Temperature gradient studies</td>
</tr>
<tr>
<td>96931</td>
<td>Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, first lesion</td>
</tr>
<tr>
<td>96932</td>
<td>Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, first lesion</td>
</tr>
<tr>
<td>96933</td>
<td>Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, first lesion</td>
</tr>
<tr>
<td>96934</td>
<td>Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, each additional lesion (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>96935</td>
<td>Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, each additional lesion (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>96936</td>
<td>Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, each additional lesion (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>S3650</td>
<td>Diagnostic test of saliva to determine hormone levels (estrogen, testosterone) and biological hormone replacement therapy</td>
</tr>
<tr>
<td>0084U</td>
<td>Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens</td>
</tr>
<tr>
<td>0086U</td>
<td>Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility</td>
</tr>
<tr>
<td>0087U</td>
<td>Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score</td>
</tr>
<tr>
<td>0088U</td>
<td>Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection</td>
</tr>
<tr>
<td>0089U</td>
<td>Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)</td>
</tr>
<tr>
<td>0090U</td>
<td>Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a categorical result (ie, benign, indeterminate, malignant)</td>
</tr>
<tr>
<td>0091U</td>
<td>Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result</td>
</tr>
<tr>
<td>0092U</td>
<td>Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy</td>
</tr>
<tr>
<td>0093U</td>
<td>Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected</td>
</tr>
<tr>
<td>0094U</td>
<td>Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis</td>
</tr>
<tr>
<td>0095U</td>
<td>Inflammation (eosinophilic esophagitis), ELISA analysis of eotaxin-3 (CCL26 [C-C motif chemokine ligand 26]) and major basic protein (PRG2 [proteoglycan 2, pro eosinophil major basic protein]), specimen obtained by swallowed nylon string, algorithm reported as predictive probability index for active eosinophilic esophagitis</td>
</tr>
<tr>
<td>0096U</td>
<td>Human papillomavirus (HPV), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>0097U</td>
<td>Gastrointestinal pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 22 targets (Campylobacter [C. jejuni/C. coli/C. upsaliensis], Clostridium difficile [C. difficile] toxin A/B, Plesiomonas shigelloides, Salmonella, Vibrio [V. parahaemolyticus/V. vulnificus/V. cholerae], including specific identification of Vibrio cholerae, Yersinia enterocolitica, Enteropathogenic Escherichia coli [EPEC], Enterotoxigenic Escherichia coli [ETEC] It/st, Shiga-like toxin-producing Escherichia coli [STEC] stx1/stx2 [including specific identification of the E. coli O157 serogroup within STEC], Shigella/Enteroinvasive Escherichia coli [EIEC], Cryptosporidium, Cyclospora cayetanensis, Entamoeba histolytica, Giardia lamblia [also known as G. intestinalis and G. duodenalis], adenovirus F 40/41, astrovirus, norovirus GI/GII, rotavirus A, sapovirus [Genogroups I, II, IV, and V])</td>
</tr>
<tr>
<td>0098U</td>
<td>Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 14 targets (adenovirus, coronavirus, human metapneumovirus, influenza A, influenza A subtype H1, influenza A subtype H3, influenza A subtype H1-2009, influenza B, parainfluenza virus, human rhinovirus/enterovirus, respiratory syncytial virus, Bordetella pertussis, Chlamyphila pneumoniae, Mycoplasma pneumoniae)</td>
</tr>
<tr>
<td>0099U</td>
<td>Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 20 targets (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus, coronavirus OC43, human metapneumovirus, influenza A, influenza A subtype, influenza A subtype H3, influenza A subtype H1-2009, influenza, parainfluenza virus, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, human rhinovirus/enterovirus, respiratory syncytial virus, Bordetella pertussis, Chlamyphila pneumoniae, Mycoplasma pneumoniae)</td>
</tr>
<tr>
<td>0100T</td>
<td>Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy</td>
</tr>
<tr>
<td>0100U</td>
<td>Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 20 targets (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus, human rhinovirus/enterovirus, influenza A, including subtypes H1, H1-2009, and H3, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, respiratory syncytial virus, Bordetella parapertussis [IS1001], Bordetella pertussis [ptxP], Chlamydia pneumoniae, Mycoplasma pneumoniae)</td>
</tr>
<tr>
<td>0101T</td>
<td>Extracorporeal shock wave involving musculoskeletal system, not otherwise specified; high energy</td>
</tr>
</tbody>
</table>
0101U Hereditary colon cancer disorders (e.g., Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNa analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])

0102T Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyly

0102U Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNa analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])

0103U Hereditary ovarian cancer (e.g., hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNa analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])

0105U Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)

0106U Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion

0107U Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method

0108U Gastroenterology (Barrett’s esophagus), whole slide–digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer

0109U Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0110U</td>
<td>Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected</td>
</tr>
<tr>
<td>0112U</td>
<td>Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene</td>
</tr>
<tr>
<td>0115U</td>
<td>Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected</td>
</tr>
<tr>
<td>0116U</td>
<td>Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications</td>
</tr>
<tr>
<td>0117U</td>
<td>Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthuric acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain</td>
</tr>
<tr>
<td>0119U</td>
<td>Cardiology, ceramides by liquid chromatography–tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events</td>
</tr>
<tr>
<td>0121U</td>
<td>Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood</td>
</tr>
<tr>
<td>0122U</td>
<td>Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood</td>
</tr>
<tr>
<td>0123U</td>
<td>Mechanical fragility, RBC, shear stress and spectral analysis profiling</td>
</tr>
<tr>
<td>0124U</td>
<td>Fetal congenital abnormalities, biochemical assays of 3 analytes (free beta-hCG, PAPP-A, AFP), time-resolved fluorescence immunoassay, maternal dried-blood spot, algorithm reported as risk scores for fetal trisomies 13/18 and 21</td>
</tr>
<tr>
<td>0125U</td>
<td>Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, maternal serum, algorithm reported as risk scores for fetal trisomies 13/18, 21, and preeclampsia</td>
</tr>
<tr>
<td>0126U</td>
<td>Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk scores for fetal trisomies 13/18, 21, and preeclampsia</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0127U</td>
<td>Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia</td>
</tr>
<tr>
<td>0128U</td>
<td>Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk score for preeclampsia</td>
</tr>
<tr>
<td>0139U</td>
<td>Neurology (autism spectrum disorder [ASD]), quantitative measurements of 6 central carbon metabolites (ie, a-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, and succinate), LC-MS/MS, plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)</td>
</tr>
<tr>
<td>0140U</td>
<td>Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected</td>
</tr>
<tr>
<td>0141U</td>
<td>Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected</td>
</tr>
<tr>
<td>0142U</td>
<td>Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected</td>
</tr>
<tr>
<td>0143U</td>
<td>Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service</td>
</tr>
<tr>
<td>0144U</td>
<td>Drug assay, definitive, 160 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service</td>
</tr>
<tr>
<td>0145U</td>
<td>Drug assay, definitive, 65 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service</td>
</tr>
<tr>
<td>0146U</td>
<td>Drug assay, definitive, 80 or more drugs or metabolites, urine, by quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td>0147U</td>
<td>Drug assay, definitive, 85 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service</td>
</tr>
<tr>
<td>0148U</td>
<td>Drug assay, definitive, 100 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service</td>
</tr>
<tr>
<td>0149U</td>
<td>Drug assay, definitive, 60 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service</td>
</tr>
<tr>
<td>0150U</td>
<td>Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service</td>
</tr>
<tr>
<td>0151U</td>
<td>Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 33 targets, real-time semi-quantitative PCR, bronchoalveolar lavage, sputum, or endotracheal aspirate, detection of 33 organismal and antibiotic resistance genes with limited semi-quantitative results</td>
</tr>
<tr>
<td>0152U</td>
<td>Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of &gt;1,000 potential microbial organisms for significant positive pathogens</td>
</tr>
<tr>
<td>0154U</td>
<td>FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C&gt;T], p.S249C [c.746C&gt;G], p.G370C [c.1108G&gt;T], p.Y373C [c.1118A&gt;G], FGFR3-TACC3v1, and FGFR3-TACC3v3)</td>
</tr>
<tr>
<td>0232T</td>
<td>Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed</td>
</tr>
<tr>
<td>0274T</td>
<td>Percutaneous laminotomy/laminectomy (intralaminar approach) for decompression of neural elements, (with or without ligamentous resection, disectomy, facetectomy and/or foraminotomy) any method under indirect image guidance (e.g., fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; cervical or thoracic</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td>0275T</td>
<td>Percutaneous laminotomy/laminectomy (intralaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy) any method under indirect image guidance (e.g., fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; cervical or thoracic, lumbar</td>
</tr>
<tr>
<td>0331T</td>
<td>Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment</td>
</tr>
<tr>
<td>0332T</td>
<td>Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT</td>
</tr>
<tr>
<td>0333T</td>
<td>Visual evoked potential, screening of visual acuity, automated</td>
</tr>
<tr>
<td>0335T</td>
<td>Extra-osseous subtalar joint implant for talotarsal stabilization</td>
</tr>
<tr>
<td>0338T</td>
<td>Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral</td>
</tr>
<tr>
<td>0339T</td>
<td>Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral</td>
</tr>
<tr>
<td>0347T</td>
<td>Placement of interstitial device(s) in bone for radiostereometric analysis (RSA)</td>
</tr>
<tr>
<td>0348T</td>
<td>Radiologic examination, radiostereometric analysis (RSA); spine, (includes, cervical, thoracic and lumbosacral, when performed)</td>
</tr>
<tr>
<td>0349T</td>
<td>Radiologic examination, radiostereometric analysis (RSA); upper extremity(ies), (includes shoulder, elbow and wrist, when performed)</td>
</tr>
<tr>
<td>0350T</td>
<td>Radiologic examination, radiostereometric analysis (RSA); lower extremity(ies), (includes hip, proximal femur, knee and ankle, when performed)</td>
</tr>
<tr>
<td>0355T</td>
<td>Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report</td>
</tr>
<tr>
<td>0378T</td>
<td>Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>0379T</td>
<td>Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0381T</td>
<td>External heart rate and 3-axis accelerometer data recording up to 14 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>0382T</td>
<td>External heart rate and 3-axis accelerometer data recording up to 14 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; review and interpretation only</td>
</tr>
<tr>
<td>0383T</td>
<td>External heart rate and 3-axis accelerometer data recording from 15 to 30 days to assess changes in heart rate to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>0384T</td>
<td>External heart rate and 3-axis accelerometer data recording from 15 to 30 days to assess changes in heart rate to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; review and interpretation only</td>
</tr>
<tr>
<td>0385T</td>
<td>External heart rate and 3-axis accelerometer data recording more than 30 days to assess changes in heart rate to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>0386T</td>
<td>External heart rate and 3-axis accelerometer data recording more than 30 days to assess changes in heart rate to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; review and interpretation only</td>
</tr>
<tr>
<td>0394T</td>
<td>High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed</td>
</tr>
<tr>
<td>0395T</td>
<td>High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed</td>
</tr>
<tr>
<td>0398T</td>
<td>Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed</td>
</tr>
<tr>
<td>0400T</td>
<td>Multi-spectral digital skin lesion analysis of clinically atypical cutaneous pigmented lesions for detection of melanomas and high risk melanocytic atypia; one to five lesions</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>0401T</td>
<td>Multi-spectral digital skin lesion analysis of clinically atypical cutaneous pigmented lesions for detection of melanomas and high risk melanocytic atypia; six or more lesions</td>
</tr>
<tr>
<td>0404T</td>
<td>Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency</td>
</tr>
<tr>
<td>0469T</td>
<td>Retinal polarization scan, ocular screening with on-site automated results, bilateral</td>
</tr>
<tr>
<td>0470T</td>
<td>Optical coherence tomography (OCT) for microstructural and morphological imaging of skin, image acquisition, interpretation, and report; first lesion</td>
</tr>
<tr>
<td>0471T</td>
<td>Optical coherence tomography (OCT) for microstructural and morphological imaging of skin, image acquisition, interpretation, and report; each additional lesion (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0472T</td>
<td>Device evaluation, interrogation, and initial programming of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional</td>
</tr>
<tr>
<td>0473T</td>
<td>Device evaluation and interrogation of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional</td>
</tr>
<tr>
<td>0474T</td>
<td>Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space</td>
</tr>
<tr>
<td>0475T</td>
<td>Recording of fetal magnetic cardiac signal using at least 3 channels; patient recording and storage, data scanning with signal extraction, technical analysis and result, as well as supervision, review, and interpretation of report by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>0476T</td>
<td>Recording of fetal magnetic cardiac signal using at least 3 channels; patient recording, data scanning, with raw electronic signal transfer of data and storage</td>
</tr>
<tr>
<td>0477T</td>
<td>Recording of fetal magnetic cardiac signal using at least 3 channels; signal extraction, technical analysis, and result</td>
</tr>
<tr>
<td>0478T</td>
<td>Recording of fetal magnetic cardiac signal using at least 3 channels; review, interpretation, report by physician or other qualified health care professional</td>
</tr>
<tr>
<td>0479T</td>
<td>Fractional ablative laser fenestration of burn and traumatic scars for functional improvement; first 100 cm² or part thereof, or 1% of body surface area of infants and children</td>
</tr>
<tr>
<td>0480T</td>
<td>Fractional ablative laser fenestration of burn and traumatic scars for functional improvement; each additional 100 cm², or each additional 1% of body surface area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0481T</td>
<td>Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed</td>
</tr>
<tr>
<td>0483T</td>
<td>Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; percutaneous approach, including transseptal puncture, when performed</td>
</tr>
<tr>
<td>0484T</td>
<td>Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; transthoracic exposure (eg, thoracotomy, transapical)</td>
</tr>
<tr>
<td>0485T</td>
<td>Optical coherence tomography (OCT) of middle ear, with interpretation and report; unilateral</td>
</tr>
<tr>
<td>0486T</td>
<td>Optical coherence tomography (OCT) of middle ear, with interpretation and report; bilateral</td>
</tr>
<tr>
<td>0487T</td>
<td>Biomechanical mapping, transvaginal, with report</td>
</tr>
<tr>
<td>0489T</td>
<td>Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells</td>
</tr>
<tr>
<td>0490T</td>
<td>Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; multiple injections in one or both hands</td>
</tr>
<tr>
<td>0491T</td>
<td>Ablative laser treatment, non-contact, full field and fractional ablation, open wound, per day, total treatment surface area; first 20 sq cm or less</td>
</tr>
<tr>
<td>0492T</td>
<td>Ablative laser treatment, non-contact, full field and fractional ablation, open wound, per day, total treatment surface area; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0493T</td>
<td>Near-infrared spectroscopy studies of lower extremity wounds (eg, for oxyhemoglobin measurement)</td>
</tr>
<tr>
<td>0494T</td>
<td>Surgical preparation and cannulation of marginal (extended) cadaver donor lung(s) to ex vivo organ perfusion system, including decannulation, separation from the perfusion system, and cold preservation of the allograft prior to implantation, when perform</td>
</tr>
<tr>
<td>0495T</td>
<td>Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; first two hours in sterile field</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>0496T</td>
<td>Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; each additional hour (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0497T</td>
<td>External patient-activated, physician- or other qualified health care professional-prescribed, electrocardiographic rhythm derived event recorder without 24 hour attended monitoring; in-office connection</td>
</tr>
<tr>
<td>0498T</td>
<td>External patient-activated, physician- or other qualified health care professional-prescribed, electrocardiographic rhythm derived event recorder without 24 hour attended monitoring; review and interpretation by a physician or other qualified health care professional per 30 days with at least one patient-generated triggered event</td>
</tr>
<tr>
<td>0499T</td>
<td>Cystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for urethral stricture or stenosis, including fluoroscopy, when performed</td>
</tr>
<tr>
<td>0500T</td>
<td>Infectious agent detection by nucleic acid (DNA or RNA), human papillomavirus (HPV) for five or more separately reported high-risk HPV types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) (ie, genotyping)</td>
</tr>
<tr>
<td>0505T</td>
<td>Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion</td>
</tr>
<tr>
<td>0506T</td>
<td>Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report</td>
</tr>
<tr>
<td>0507T</td>
<td>Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report</td>
</tr>
<tr>
<td>0508T</td>
<td>Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia</td>
</tr>
<tr>
<td>0509T</td>
<td>Electroretinography (ERG) with interpretation and report, pattern (PERG)</td>
</tr>
<tr>
<td>0510T</td>
<td>Removal of sinus tarsi implant</td>
</tr>
<tr>
<td>0511T</td>
<td>Removal and reinsertion of sinus tarsi implant</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0512T</td>
<td>Extracorporeal shock wave for integumentary wound healing, high energy,</td>
</tr>
<tr>
<td></td>
<td>including topical application and dressing care; initial wound</td>
</tr>
<tr>
<td>0513T</td>
<td>Extracorporeal shock wave for integumentary wound healing, high energy,</td>
</tr>
<tr>
<td></td>
<td>including topical application and dressing care; each additional wound (List</td>
</tr>
<tr>
<td></td>
<td>separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0514T</td>
<td>Intraoperative visual axis identification using patient fixation (List</td>
</tr>
<tr>
<td></td>
<td>separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0515T</td>
<td>Insertion of wireless cardiac stimulator for left ventricular pacing,</td>
</tr>
<tr>
<td></td>
<td>including device interrogation and programming, and imaging supervision</td>
</tr>
<tr>
<td></td>
<td>and interpretation, when performed; complete system (includes electrode</td>
</tr>
<tr>
<td></td>
<td>and generator [transmitter and battery])</td>
</tr>
<tr>
<td>0516T</td>
<td>Insertion of wireless cardiac stimulator for left ventricular pacing,</td>
</tr>
<tr>
<td></td>
<td>including device interrogation and programming, and imaging supervision and</td>
</tr>
<tr>
<td></td>
<td>interpretation, when performed; electrode only</td>
</tr>
<tr>
<td>0517T</td>
<td>Insertion of wireless cardiac stimulator for left ventricular pacing,</td>
</tr>
<tr>
<td></td>
<td>including device interrogation and programming, and imaging supervision and</td>
</tr>
<tr>
<td></td>
<td>interpretation, when performed; pulse generator component(s) (battery and/or</td>
</tr>
<tr>
<td></td>
<td>transmitter) only</td>
</tr>
<tr>
<td>0518T</td>
<td>Removal of only pulse generator component(s) (battery and/or transmitter)</td>
</tr>
<tr>
<td></td>
<td>of wireless cardiac stimulator for left ventricular pacing</td>
</tr>
<tr>
<td>0519T</td>
<td>Removal and replacement of wireless cardiac stimulator for left ventricular</td>
</tr>
<tr>
<td></td>
<td>pacing; pulse generator component(s) (battery and/or transmitter)</td>
</tr>
<tr>
<td>0520T</td>
<td>Removal and replacement of wireless cardiac stimulator for left ventricular</td>
</tr>
<tr>
<td></td>
<td>pacing; pulse generator component(s) (battery and/or transmitter),</td>
</tr>
<tr>
<td></td>
<td>including placement of a new electrode</td>
</tr>
<tr>
<td>0521T</td>
<td>Interrogation device evaluation (in person) with analysis, review and</td>
</tr>
<tr>
<td></td>
<td>report, includes connection, recording, and disconnection per patient</td>
</tr>
<tr>
<td></td>
<td>encounter, wireless cardiac stimulator for left ventricular pacing</td>
</tr>
<tr>
<td>0522T</td>
<td>Programming device evaluation (in person) with iterative adjustment of the</td>
</tr>
<tr>
<td></td>
<td>implantable device to test the function of the device and select optimal</td>
</tr>
<tr>
<td></td>
<td>permanent programmed values with analysis, including review and report,</td>
</tr>
<tr>
<td></td>
<td>wireless cardiac stimulator for left ventricular pacing</td>
</tr>
<tr>
<td>0523T</td>
<td>Intraprocedural coronary fractional flow reserve (FFR) with 3D functional</td>
</tr>
<tr>
<td></td>
<td>mapping of color-coded FFR values for the coronary tree, derived from</td>
</tr>
<tr>
<td></td>
<td>coronary angiogram data, for real-time review and interpretation of</td>
</tr>
<tr>
<td></td>
<td>possible atherosclerotic stenosis(es) intervention (List separately in</td>
</tr>
<tr>
<td></td>
<td>addition to code for primary procedure)</td>
</tr>
<tr>
<td>0524T</td>
<td>Endovenous catheter directed chemical ablation with balloon isolation of</td>
</tr>
<tr>
<td></td>
<td>incompetent extremity vein, open or percutaneous, including all vascular</td>
</tr>
<tr>
<td></td>
<td>access, catheter manipulation, diagnostic imaging, imaging guidance and</td>
</tr>
<tr>
<td></td>
<td>monitoring</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0525T</td>
<td>Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)</td>
</tr>
<tr>
<td>0526T</td>
<td>Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only</td>
</tr>
<tr>
<td>0527T</td>
<td>Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only</td>
</tr>
<tr>
<td>0528T</td>
<td>Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report</td>
</tr>
<tr>
<td>0529T</td>
<td>Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report</td>
</tr>
<tr>
<td>0530T</td>
<td>Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)</td>
</tr>
<tr>
<td>0531T</td>
<td>Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only</td>
</tr>
<tr>
<td>0532T</td>
<td>Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only</td>
</tr>
<tr>
<td>0533T</td>
<td>Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review</td>
</tr>
<tr>
<td>0534T</td>
<td>Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor</td>
</tr>
<tr>
<td>0535T</td>
<td>Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration</td>
</tr>
<tr>
<td>0536T</td>
<td>Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report</td>
</tr>
<tr>
<td>0541T</td>
<td>Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles,</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td>0542T</td>
<td>Machine learning-derived clinical scoring, and automated report generation, single study;</td>
</tr>
<tr>
<td>0543T</td>
<td>Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study; interpretation and report</td>
</tr>
<tr>
<td>0544T</td>
<td>Transapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae</td>
</tr>
<tr>
<td>0545T</td>
<td>Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture</td>
</tr>
<tr>
<td>0546T</td>
<td>Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach</td>
</tr>
<tr>
<td>0547T</td>
<td>Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report</td>
</tr>
<tr>
<td>0548T</td>
<td>Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score</td>
</tr>
<tr>
<td>0549T</td>
<td>Transperineal periurethral balloon continence device; bilateral placement, including cystoscopy and fluoroscopy</td>
</tr>
<tr>
<td>0550T</td>
<td>unilateral placement, including cystoscopy and fluoroscopy</td>
</tr>
<tr>
<td>0551T</td>
<td>removal, each balloon</td>
</tr>
<tr>
<td>0552T</td>
<td>adjustment of balloon(s) fluid volume</td>
</tr>
<tr>
<td>0553T</td>
<td>Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>0554T</td>
<td>Percutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention</td>
</tr>
<tr>
<td>0555T</td>
<td>Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report</td>
</tr>
<tr>
<td>0556T</td>
<td>retrieval and transmission of the scan data</td>
</tr>
<tr>
<td>0557T</td>
<td>assessment of bone strength and fracture risk and bone mineral density</td>
</tr>
<tr>
<td>0558T</td>
<td>interpretation and report</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0558T</td>
<td>Computed tomography scan taken for the purpose of biomechanical computed tomography analysis</td>
</tr>
<tr>
<td>0559T</td>
<td>Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure</td>
</tr>
<tr>
<td>0560T</td>
<td>each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0561T</td>
<td>Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide</td>
</tr>
<tr>
<td>0562T</td>
<td>each additional anatomic guide (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0563T</td>
<td>Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral</td>
</tr>
<tr>
<td>0564T</td>
<td>Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations</td>
</tr>
<tr>
<td>0565T</td>
<td>Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation</td>
</tr>
<tr>
<td>0566T</td>
<td>Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral</td>
</tr>
<tr>
<td>0567T</td>
<td>Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound</td>
</tr>
<tr>
<td>0568T</td>
<td>Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound</td>
</tr>
<tr>
<td>0569T</td>
<td>Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis</td>
</tr>
<tr>
<td>0570T</td>
<td>Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0571T</td>
<td>Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed</td>
</tr>
<tr>
<td>0572T</td>
<td>Insertion of substernal implantable defibrillator electrode</td>
</tr>
<tr>
<td>0573T</td>
<td>Removal of substernal implantable defibrillator electrode</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>0574T</td>
<td>Repositioning of previously implanted substernal implantable defibrillator-pacing electrode</td>
</tr>
<tr>
<td>0575T</td>
<td>Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>0576T</td>
<td>Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter</td>
</tr>
<tr>
<td>0577T</td>
<td>Electrophysiological evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)</td>
</tr>
<tr>
<td>0578T</td>
<td>Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>0579T</td>
<td>Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results</td>
</tr>
<tr>
<td>0580T</td>
<td>Removal of substernal implantable defibrillator pulse generator only</td>
</tr>
<tr>
<td>0581T</td>
<td>Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral</td>
</tr>
<tr>
<td>0582T</td>
<td>Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance</td>
</tr>
<tr>
<td>0583T</td>
<td>Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia</td>
</tr>
<tr>
<td>0584T</td>
<td>Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous</td>
</tr>
<tr>
<td>0585T</td>
<td>Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic</td>
</tr>
<tr>
<td>0586T</td>
<td>Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0587T</td>
<td>Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve</td>
</tr>
<tr>
<td>0588T</td>
<td>Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve</td>
</tr>
<tr>
<td>0589T</td>
<td>Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters</td>
</tr>
<tr>
<td>0590T</td>
<td>Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters</td>
</tr>
<tr>
<td>0591T</td>
<td>Health and well-being coaching face-to-face; individual, initial assessment</td>
</tr>
<tr>
<td>0592T</td>
<td>Health and well-being coaching face-to-face; individual, follow-up session, at least 30 minutes</td>
</tr>
<tr>
<td>0593T</td>
<td>Health and well-being coaching face-to-face; group (2 or more individuals), at least 30 minutes</td>
</tr>
<tr>
<td>A4563</td>
<td>Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each</td>
</tr>
<tr>
<td>A9285</td>
<td>Inversion/eversion correction device</td>
</tr>
<tr>
<td>A9286</td>
<td>Hygienic item or device, disposable or non-disposable, any type, each</td>
</tr>
<tr>
<td>Acupressure</td>
<td>Acupressure Energy medicine.</td>
</tr>
<tr>
<td>Anser ADA, Anser IFX Lab Tests</td>
<td>Anser ADA and Anser IFX lab tests, refreshed benchmarking and Hayes</td>
</tr>
<tr>
<td>B4105</td>
<td>In-line cartridge containing digestive enzyme(s) for enteral feeding, each</td>
</tr>
<tr>
<td>C1734</td>
<td>Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to-bone (implantable)</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>C1821</td>
<td>Interspinous process distraction device (implantable)</td>
</tr>
<tr>
<td>C1824</td>
<td>Generator, cardiac contractility modulation (implantable)</td>
</tr>
<tr>
<td>C1839</td>
<td>Iris prosthesis</td>
</tr>
<tr>
<td>C1841</td>
<td>Retinal prosthesis, includes all internal and external components</td>
</tr>
<tr>
<td>C1982</td>
<td>Catheter, pressure generating, one-way valve, intermittently occlusive</td>
</tr>
<tr>
<td>C2596</td>
<td>Probe, image guided, robotic, waterjet ablation</td>
</tr>
<tr>
<td>C2613</td>
<td>Lung Biopsy Plug with Delivery System</td>
</tr>
<tr>
<td>C2624</td>
<td>Implantable wireless pulmonary artery pressure sensor with delivery catheter,</td>
</tr>
<tr>
<td></td>
<td>including all system components</td>
</tr>
<tr>
<td>C9047</td>
<td>Injection, caplacizumab-yhdp, 1 mg</td>
</tr>
<tr>
<td>C9054</td>
<td>Injection, lefamulin (Xenleta), 1 mg</td>
</tr>
<tr>
<td>C9132</td>
<td>Prothrombin complex concentrate (human), Kcentra, per IU of Factor IX activity</td>
</tr>
<tr>
<td>C9407</td>
<td>Iodine i-131 iobenguane, diagnostic, 1 millicurie</td>
</tr>
<tr>
<td>C9734</td>
<td>Focused ultrasound ablation/therapeutic intervention, other than uterine</td>
</tr>
<tr>
<td></td>
<td>leiomyomata, with magnetic resonance (MR) guidance</td>
</tr>
<tr>
<td>C9745</td>
<td>Nasal endoscopy, surgical; balloon dilation of eustachian tube</td>
</tr>
<tr>
<td>C9747</td>
<td>Ablation of prostate, transrectal, high intensity focused ultrasound (HIFU),</td>
</tr>
<tr>
<td></td>
<td>including imaging guidance</td>
</tr>
<tr>
<td>C9751</td>
<td>Bronchoscopy, rigid or flexible, transbrachial ablation of lesion(s) by</td>
</tr>
<tr>
<td></td>
<td>microwave energy, including fluoroscopic guidance, when performed, with</td>
</tr>
<tr>
<td></td>
<td>computed tomography acquisition(s) and 3-d rendering, computer-assisted,</td>
</tr>
<tr>
<td></td>
<td>image-guided navigation, and endobronchial ultrasound (ebus)</td>
</tr>
<tr>
<td></td>
<td>guided transtracheal and/or transbrachial sampling (eg, aspiration[5]/biopsy[5])</td>
</tr>
<tr>
<td></td>
<td>and all mediastinal and/or hilar lymph node stations or structures and</td>
</tr>
<tr>
<td></td>
<td>therapeutic intervention(s)</td>
</tr>
<tr>
<td>C9752</td>
<td>Destruction of intraosseous basivertebral nerve, first two vertebral bodies,</td>
</tr>
<tr>
<td></td>
<td>including imaging guidance (e.g., fluoroscopy), lumbar/sacrum</td>
</tr>
<tr>
<td>C9753</td>
<td>Destruction of intraosseous basivertebral nerve, each additional vertebral</td>
</tr>
<tr>
<td></td>
<td>body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum</td>
</tr>
<tr>
<td></td>
<td>(list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>C9754</td>
<td>Creation of arteriovenous fistula, percutaneous; direct, any site, including</td>
</tr>
<tr>
<td></td>
<td>all imaging and radiologic supervision and interpretation, when performed</td>
</tr>
<tr>
<td></td>
<td>and secondary procedures to redirect blood flow (e.g., transluminal balloon</td>
</tr>
<tr>
<td></td>
<td>angioplasty, coil embolization, when performed</td>
</tr>
<tr>
<td>C9755</td>
<td>Creation of arteriovenous fistula, percutaneous using magnetic-guided arterial</td>
</tr>
<tr>
<td></td>
<td>and venous catheters and radiofrequency energy, including flow-directing</td>
</tr>
<tr>
<td></td>
<td>procedures (e.g., vascular coil embolization with radiologic supervision and</td>
</tr>
<tr>
<td></td>
<td>interpretation,</td>
</tr>
</tbody>
</table>
when performed) and fistulogram(s), angiography, venography, and/or ultrasound, with radiologic supervision and interpretation, when performed

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9756</td>
<td>Intraoperative near-infrared fluorescence lymphatic mapping of lymph node(s) (sentinel or tumor draining) with administration of indocyanine green (ICG) (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>C9757</td>
<td>Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar</td>
</tr>
<tr>
<td>C9758</td>
<td>Blinded procedure for NYHA Class III/IV heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study</td>
</tr>
</tbody>
</table>

**Cefaly Device**

Cefaly is a small, portable, battery-powered, prescription device that resembles a plastic headband worn across the forehead and atop the ears as a treatment for migraines.

**Cold Caps and Cold Cap Systems**

Cold Caps including but not limited to DigniCap, Arctic, Paxman Scalp, Polar, Penguin, Chemo, ElastoGels, and Moleskin Plus brands.

**Corus CAD Gene Expression test**

Corus Coronary Artery Disease Gene Expression test.

**Craniosacral therapy**

Craniosacral Therapy also referred to as cranial osteopathy, cranial therapy, bio-cranial therapy, bio cranial stretching, Craniotherapy, Sacro Occipital technique, involves intrinsic movements of the bones of the skull which are believed to reveal different rhythmic tidal motions in the body.

**E0446**

Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories.

**E0770**

Functional Electrical Stimulation Device

**Epilepsy Watch**

Epilepsy Watch - called Embrace.

**Fisher Wallace stimulator**

Fisher Wallace stimulator.
<table>
<thead>
<tr>
<th>Service</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>GeneSight Testing</td>
<td>There is interest in the use of genetic testing to help in medication selection for psychiatric conditions</td>
</tr>
<tr>
<td>Hair Follicle Toxic Element Exposure Profile test</td>
<td>A Metals Hair Test is ideal for checking current exposure to toxic metals</td>
</tr>
<tr>
<td>High Energy Shock Wave Therapy</td>
<td>ESWT for foot conditions is not covered</td>
</tr>
<tr>
<td>Homeopathic Sports Therapy</td>
<td>Homeopathic sports therapy</td>
</tr>
<tr>
<td>Integrative Medicine Consults</td>
<td>Integrative Medicine Consults</td>
</tr>
<tr>
<td>J0121</td>
<td>Injection, omadacycline, 1 mg</td>
</tr>
<tr>
<td>J0179</td>
<td>Injection, brolucizumab-dbl, 1 mg</td>
</tr>
<tr>
<td>J0593</td>
<td>Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)</td>
</tr>
<tr>
<td>J3111</td>
<td>Injection, romosozumab-aqqg, 1 mg</td>
</tr>
<tr>
<td>J3245</td>
<td>Injection, tildrakizumab, 1 mg</td>
</tr>
<tr>
<td>J3570</td>
<td>Laetrile</td>
</tr>
<tr>
<td>J7208</td>
<td>Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.</td>
</tr>
<tr>
<td>J7329</td>
<td>Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg</td>
</tr>
<tr>
<td>J7331</td>
<td>Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg</td>
</tr>
<tr>
<td>J7332</td>
<td>Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg</td>
</tr>
<tr>
<td>J7677</td>
<td>Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through DME, 1 microgram</td>
</tr>
<tr>
<td>J9118</td>
<td>Injection, calaspargase pegol-mknl, 10 units</td>
</tr>
<tr>
<td>J9119</td>
<td>Injection, cemiplimab-rwlc, 1 mg</td>
</tr>
<tr>
<td>J9210</td>
<td>Injection, emapalumab-lzsg, 1 mg</td>
</tr>
<tr>
<td>J9269</td>
<td>Injection, tgraxofusp-erzs, 10 micrograms</td>
</tr>
<tr>
<td>J9309</td>
<td>Injection, polatuzumab vedotin-piiq, 1 mg</td>
</tr>
<tr>
<td>J9313</td>
<td>Injection, moxetumomab pasudotox-tdfk, 0.01 mg</td>
</tr>
<tr>
<td>K1001</td>
<td>Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>K1002</td>
<td>Cranial electrotherapy stimulation (CES) system, includes all supplies and</td>
</tr>
<tr>
<td></td>
<td>accessories, any type</td>
</tr>
<tr>
<td>K1004</td>
<td>Low frequency ultrasonic diathermy treatment device for home use, includes</td>
</tr>
<tr>
<td></td>
<td>all components and accessories</td>
</tr>
<tr>
<td>L2006</td>
<td>Knee-ankle-foot (KAF) device, any material, single or double upright, swing</td>
</tr>
<tr>
<td></td>
<td>and/or stance phase microprocessor control with adjustability, includes all</td>
</tr>
<tr>
<td></td>
<td>components (e.g., sensors, batteries, charger), any type activation, with</td>
</tr>
<tr>
<td></td>
<td>or without ankle joint(s), custom fabricated</td>
</tr>
<tr>
<td>L3674</td>
<td>Shoulder orthotic, abduction positioning (airplane design), thoracic</td>
</tr>
<tr>
<td></td>
<td>component and support bar, with or without nontorsion joint/turnbuckle,</td>
</tr>
<tr>
<td></td>
<td>may include soft interface, straps, custom fabricated, includes fitting and</td>
</tr>
<tr>
<td></td>
<td>adjustment</td>
</tr>
<tr>
<td>L5961</td>
<td>Addition, endoskeletal system, polycentric hip joint, pneumatic or hydraulic</td>
</tr>
<tr>
<td></td>
<td>rotation control, with or without flexion and/or extension control</td>
</tr>
<tr>
<td>L8605</td>
<td>Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant,</td>
</tr>
<tr>
<td></td>
<td>anal canal, 1 ml, includes shipping and necessary supplies</td>
</tr>
<tr>
<td>L8608</td>
<td>Miscellaneous external component, supply or accessory for use with the argus</td>
</tr>
<tr>
<td></td>
<td>ii retinal prosthesysystem</td>
</tr>
<tr>
<td>L8701</td>
<td>Powered upper extremity range of motion assist device, elbow, wrist, hand</td>
</tr>
<tr>
<td></td>
<td>with single or double upright(s), includes microprocessor, sensors, all</td>
</tr>
<tr>
<td></td>
<td>components and accessories, custom fabricated</td>
</tr>
<tr>
<td>L8702</td>
<td>Powered upper extremity range of motion assist device, elbow, wrist, hand,</td>
</tr>
<tr>
<td></td>
<td>finger, single or double upright(s), includes microprocessor, sensors, all</td>
</tr>
<tr>
<td></td>
<td>components and accessories, custom fabricated</td>
</tr>
<tr>
<td>M0076</td>
<td>Prolotherapy</td>
</tr>
<tr>
<td>Linx Reflux Management System</td>
<td>The LINX Reflux Management System. Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device</td>
</tr>
<tr>
<td>Massage Therapy</td>
<td>Massage Therapy performed by a massage therapist.</td>
</tr>
<tr>
<td>MySentry by MedTronics.</td>
<td>Remote Glucose Monitoring for patients with type 1 diabetes (including pregnant women with poorly controlled type 1 diabetes)</td>
</tr>
<tr>
<td>Nail Fungus Laser Surgery</td>
<td>Treatment of nail fungus with laser</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Active Release Therapy (ART) is a type of massage therapy</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Relizorb Cartridge (pancreatic enzyme packed medication cartridge)</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Description</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td>Oasis Pro CES Device- Cranio-Electro Stimulation</td>
</tr>
<tr>
<td></td>
<td>Upper Limb Myoelectric Orthosis</td>
</tr>
<tr>
<td></td>
<td>Wilderness Therapy</td>
</tr>
<tr>
<td></td>
<td>Monalisa Touch</td>
</tr>
<tr>
<td></td>
<td>Pantaloons</td>
</tr>
<tr>
<td></td>
<td>heel ultrasound as a bone density screening</td>
</tr>
<tr>
<td></td>
<td>Laser treatment for Lichen sclerosus</td>
</tr>
<tr>
<td></td>
<td>FlexiGraft</td>
</tr>
<tr>
<td></td>
<td>Symfony Toric vision intraocular lenses</td>
</tr>
<tr>
<td></td>
<td>Schroth method of Physical Therapy</td>
</tr>
<tr>
<td></td>
<td>Latera Absorbable Nasal Implant</td>
</tr>
<tr>
<td></td>
<td>Reiki</td>
</tr>
<tr>
<td></td>
<td>Central Auditory Processing Disorder Hearing Exam</td>
</tr>
<tr>
<td></td>
<td>Proton Beam Radiation Therapy for Prostate Cancer</td>
</tr>
<tr>
<td></td>
<td>Game Ready Cooling and Compression Devices</td>
</tr>
<tr>
<td></td>
<td>Dry Needling</td>
</tr>
<tr>
<td></td>
<td>Per Oral Endoscopic Myotomy (POEM)</td>
</tr>
<tr>
<td></td>
<td>Coolief Radiofrequency Device and Treatment</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Active release technique (ART) by Chiropractor</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Iontophoresis Device for the treatment of hyperhidrosis for use in the home</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Embrace 2 seizure monitoring smart wristband</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Laser treatment to rosacea with an IPL beam or Excel V beam</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Ketamine IV Infusion for the treatment of social anxiety and resistant depression disorders</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Implantable hormone pellets for the treatment of menopausal symptoms (PRE MENOPAUSE)</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Ozone Therapy/Oxidative Therapy</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Whole Body Hyperthermia treatment for Lyme Disease</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Lidocaine Infusion-for pain management</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Cranial electrotherapy stimulation (CES), also known as cranial electrical stimulation, transcranial electrical stimulation, or electrical stimulation therapy for the treatment of anxiety and migraines using a device called Alpha-Stim</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Genecept Assay</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>BiowaveGO Neuromodulation Pain Therapy Device</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Macrilen (Macimorlen) is a growth hormone (GH) secretagogue receptor agonist indicated for the diagnosis of adult growth hormone deficiency</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>Gammacore Non-Invasive Vagus Nerve Stimulator for headaches</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>CARTIVA® SCI Synthetic Cartilage Implant for Joint Pain</td>
</tr>
<tr>
<td>No Specific Code</td>
<td>miraDry for reduce underarm sweat</td>
</tr>
<tr>
<td>Pulsed RF ablation</td>
<td>Radiofrequency (RF) treatment is a minimally invasive procedure that has been used for treating various chronic pain syndromes</td>
</tr>
<tr>
<td>Q4159</td>
<td>Affinity, per square centimeter</td>
</tr>
<tr>
<td>Q4160</td>
<td>Nushield, per square centimeter</td>
</tr>
<tr>
<td>Q4161</td>
<td>Bio-ConneKt wound matrix, per sq cm</td>
</tr>
<tr>
<td>Q4176</td>
<td>Neopatch, per square centimeter</td>
</tr>
<tr>
<td>Q4177</td>
<td>Floweramnioflo, 0.1 cc</td>
</tr>
<tr>
<td>Q4178</td>
<td>Floweramniopatch, per square centimeter</td>
</tr>
<tr>
<td>Q4179</td>
<td>Flowerderm, per square centimeter</td>
</tr>
<tr>
<td>Q4180</td>
<td>Revita, per square centimeter</td>
</tr>
<tr>
<td>Q4181</td>
<td>Amnio wound, per square centimeter</td>
</tr>
<tr>
<td>Q4182</td>
<td>Transcyte, per square centimeter</td>
</tr>
<tr>
<td>Q4183</td>
<td>Surgigraft, per square centimeter</td>
</tr>
<tr>
<td>Q4184</td>
<td>Cellesta, per square centimeter</td>
</tr>
<tr>
<td>Q4185</td>
<td>Cellesta flowable amnion (25 mg per cc); per 0.5 cc</td>
</tr>
<tr>
<td>Q4186</td>
<td>Epifix, per square centimeter</td>
</tr>
<tr>
<td>Q4187</td>
<td>Epicord, per square centimeter</td>
</tr>
<tr>
<td>Q4188</td>
<td>Amnioarmor, per square centimeter</td>
</tr>
<tr>
<td>Q4189</td>
<td>Artacent ac, 1 mg</td>
</tr>
<tr>
<td>Q4190</td>
<td>Artacent ac, per square centimeter</td>
</tr>
<tr>
<td>Q4191</td>
<td>Restorigin, per square centimeter</td>
</tr>
<tr>
<td>Q4192</td>
<td>Restorigin, 1 cc</td>
</tr>
<tr>
<td>Q4193</td>
<td>Coll-e-derm, per square centimeter</td>
</tr>
<tr>
<td>Q4194</td>
<td>Novachor, per square centimeter</td>
</tr>
<tr>
<td>Q4195</td>
<td>Puraply, per square centimeter</td>
</tr>
<tr>
<td>Q4196</td>
<td>Puraply am, per square centimeter</td>
</tr>
<tr>
<td>Q4197</td>
<td>Puraply xt, per square centimeter</td>
</tr>
<tr>
<td>Q4198</td>
<td>Genesis amniotic membrane, per square centimeter</td>
</tr>
<tr>
<td>Q4200</td>
<td>Skin te, per square centimeter</td>
</tr>
<tr>
<td>Q4201</td>
<td>Matrion, per square centimeter</td>
</tr>
<tr>
<td>Q4202</td>
<td>Keroxx (2.5g/cc), 1cc</td>
</tr>
<tr>
<td>Q4203</td>
<td>Derma-gide, per square centimeter</td>
</tr>
<tr>
<td>Q4204</td>
<td>Xwrap, per square centimeter</td>
</tr>
<tr>
<td>Q4205</td>
<td>Membrane graft or membrane wrap, per square centimeter</td>
</tr>
<tr>
<td>Q4206</td>
<td>Fluid flow or fluid GF, 1 cc</td>
</tr>
<tr>
<td>Q4208</td>
<td>Novafix, per square centimeter</td>
</tr>
<tr>
<td>Q4209</td>
<td>Surgraft, per square centimeter</td>
</tr>
<tr>
<td>Q4210</td>
<td>Axolotl graft or axolotl dualgraft, per square centimeter</td>
</tr>
<tr>
<td>Q4211</td>
<td>Amnion bio or Axobiomembrane, per square centimeter</td>
</tr>
<tr>
<td>Q4212</td>
<td>Allogen, per cc</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Q4213</td>
<td>Ascent, 0.5 mg</td>
</tr>
<tr>
<td>Q4214</td>
<td>Cellesta cord, per square centimeter</td>
</tr>
<tr>
<td>Q4215</td>
<td>Axolotl ambient or axolotl cryo, 0.1 mg</td>
</tr>
<tr>
<td>Q4216</td>
<td>Artacent cord, per square centimeter</td>
</tr>
<tr>
<td>Q4217</td>
<td>Woundfix, BioWound, Woundfix Plus, BioWound Plus, BioWound Xplus or BioWound Xplus, per square centimeter</td>
</tr>
<tr>
<td>Q4218</td>
<td>Surgicord, per square centimeter</td>
</tr>
<tr>
<td>Q4219</td>
<td>Surgigraft-dual, per square centimeter</td>
</tr>
<tr>
<td>Q4220</td>
<td>BellaCell HD or Surederm, per square centimeter</td>
</tr>
<tr>
<td>Q4221</td>
<td>Amniowrap2, per square centimeter</td>
</tr>
<tr>
<td>Q4222</td>
<td>Progenamatrix, per square centimeter</td>
</tr>
<tr>
<td>Q4226</td>
<td>MyOwn skin, includes harvesting and preparation procedures, per square centimeter</td>
</tr>
<tr>
<td>Q5109</td>
<td>Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg</td>
</tr>
<tr>
<td>Q5112</td>
<td>Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg</td>
</tr>
<tr>
<td>Q5113</td>
<td>Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg</td>
</tr>
<tr>
<td>Q5114</td>
<td>Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg</td>
</tr>
<tr>
<td>Q5115</td>
<td>Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg</td>
</tr>
<tr>
<td>Q5116</td>
<td>Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg</td>
</tr>
<tr>
<td>Q5117</td>
<td>Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg</td>
</tr>
<tr>
<td>Q5118</td>
<td>Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg</td>
</tr>
<tr>
<td>Q9982</td>
<td>Flutemetamol F18, diagnostic, per study dose, up to 5 millicuries</td>
</tr>
<tr>
<td>Q9983</td>
<td>Florbetaben F18, diagnostic, per study dose, up to 8.1 millicuries</td>
</tr>
<tr>
<td>S3722</td>
<td>Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil</td>
</tr>
<tr>
<td>S8080</td>
<td>Scintimammography (radioimmunoscintigraphy of the breast), unilateral, including supply of radiopharmaceutical</td>
</tr>
<tr>
<td>S8130</td>
<td>Interferential current stimulator, 2 channel</td>
</tr>
<tr>
<td>S8131</td>
<td>Interferential current stimulator, 4 channel</td>
</tr>
<tr>
<td>S8948</td>
<td>Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes Low Level laser Therapy (aka Red-Light Therapy) or Low-Level Laser Therapy (aka Red-Light Therapy)</td>
</tr>
<tr>
<td>S9034</td>
<td>Extracorporeal shockwave lithotripsy for gall stones</td>
</tr>
<tr>
<td>S9090</td>
<td>Vertebral axial decompression, per session</td>
</tr>
<tr>
<td>Service Dogs</td>
<td>A service dog is a type of assistance dog specifically trained to help people who have disabilities including visual difficulties, hearing impairments, mental illness, seizures, diabetes, autism, and more.</td>
</tr>
<tr>
<td>Shock Wave Therapy</td>
<td>ESWT for foot conditions is not covered</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Speech Therapy tool’ Speech Buddies</td>
<td>Speech Buddies Tools can help anyone over four years old that has problems with one or more of the R, S, L, SH, or CH sounds.</td>
</tr>
<tr>
<td>Stem Cell Therapy</td>
<td>Stem Cell therapy for the treatment of osteoarthritis</td>
</tr>
<tr>
<td>Thermal Shrinkage</td>
<td>Also referred to as Electrothermal Shrinkage or Thermal Capsulorrhaphy</td>
</tr>
<tr>
<td>Vestibular Evoked Myogenic Potential Testing (VEMP) or VsEP</td>
<td>The oVEMP test differs from another vestibular-evoked myogenic potential recorded by surface EMG electrodes over the sternocleidomastoid muscles in that the cervical vestibular-evoked myogenic potential (cVEMP) due to saccular activation is measured.</td>
</tr>
</tbody>
</table>

**Effective**

May 2020: Annual update.
March 1, 2020: Codes updated.
October 1, 2019: Codes updated.
May 2019: Code update.
December 2018: Annual update.
October 2018: Added additional codes.
April 2018: Added Codes.
April 2017: Added language to include General laws.
February 2017: Annual update.
February 2016: Annual update.
February 2015: Effective date.

**References**

General Laws of Massachusetts Chapter 175: Section 47K. Off-label drug use; cancer treatment

General Laws of Massachusetts Chapter 175: Section 47O. HIV/AIDS treatment; insurance coverage for certain off-label use of prescription drugs

General Laws of Massachusetts Chapter 176G: Section 4F. Group health maintenance contracts; coverage for bone marrow transplants
General Laws of Massachusetts Chapter 176G: Section 4G. Off-label use of prescription drugs for HIV/AIDS treatment

Public Law 111 - 148 - Patient Protection and Affordable Care Act, Section 2709